Similarly, a poorer survival of metastatic patients with BRAF or NRAS tumor mutations [10] and of patients with BRAF-mutant tumors after treatment with temozolomide and bevacizumab [11] was reported before. This evidence concerns the gene BRAF and neoplasm.